Pharmaceutical developer Fujisawa USA of Deerfield, IL, announced March 31 that it is selling its generics business to American Pharmaceutical Partners of Santa Monica, CA. Fujisawa plans to retain its proprietary drug business, which includes the
Pharmaceutical developer Fujisawa USA of Deerfield, IL, announced March 31 that it is selling its generics business to American Pharmaceutical Partners of Santa Monica, CA. Fujisawa plans to retain its proprietary drug business, which includes the cardiac stress agent Adenoscan and cardiac therapy drug Adenocard. Both products are licensed from Medco Research of Research Triangle Park, NC. Fujisawa expects to complete the sale of its generics business by May. At that point, Fujisawa will restructure its remaining proprietary pharmaceutical business as a new corporate entity, Fujisawa Healthcare.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.